![Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer's disease - Biological Psychiatry Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer's disease - Biological Psychiatry](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/2005983711/2026710125/gr1.gif)
Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer's disease - Biological Psychiatry
![Drug and Exercise Treatment of Alzheimer Disease and Mild Cognitive Impairment: A Systematic Review and Meta-Analysis of Effects on Cognition in Randomized Controlled Trials - ScienceDirect Drug and Exercise Treatment of Alzheimer Disease and Mild Cognitive Impairment: A Systematic Review and Meta-Analysis of Effects on Cognition in Randomized Controlled Trials - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1064748115002134-gr2a.jpg)
Drug and Exercise Treatment of Alzheimer Disease and Mild Cognitive Impairment: A Systematic Review and Meta-Analysis of Effects on Cognition in Randomized Controlled Trials - ScienceDirect
![IJMS | Free Full-Text | Inhibitors of Acetylcholinesterase and Butyrylcholinesterase Meet Immunity | HTML IJMS | Free Full-Text | Inhibitors of Acetylcholinesterase and Butyrylcholinesterase Meet Immunity | HTML](https://www.mdpi.com/ijms/ijms-15-09809/article_deploy/html/images/ijms-15-09809-g002.png)
IJMS | Free Full-Text | Inhibitors of Acetylcholinesterase and Butyrylcholinesterase Meet Immunity | HTML
![Molecules | Free Full-Text | Exploring the Multi-Target Performance of Mitochondriotropic Antioxidants against the Pivotal Alzheimer's Disease Pathophysiological Hallmarks | HTML Molecules | Free Full-Text | Exploring the Multi-Target Performance of Mitochondriotropic Antioxidants against the Pivotal Alzheimer's Disease Pathophysiological Hallmarks | HTML](https://www.mdpi.com/molecules/molecules-25-00276/article_deploy/html/images/molecules-25-00276-g001.png)
Molecules | Free Full-Text | Exploring the Multi-Target Performance of Mitochondriotropic Antioxidants against the Pivotal Alzheimer's Disease Pathophysiological Hallmarks | HTML
![Pharmaceutics | Free Full-Text | Hierarchical Porous Carbon—PLLA and PLGA Hybrid Nanoparticles for Intranasal Delivery of Galantamine for Alzheimer's Disease Therapy | HTML Pharmaceutics | Free Full-Text | Hierarchical Porous Carbon—PLLA and PLGA Hybrid Nanoparticles for Intranasal Delivery of Galantamine for Alzheimer's Disease Therapy | HTML](https://www.mdpi.com/pharmaceutics/pharmaceutics-12-00227/article_deploy/html/images/pharmaceutics-12-00227-g004.png)
Pharmaceutics | Free Full-Text | Hierarchical Porous Carbon—PLLA and PLGA Hybrid Nanoparticles for Intranasal Delivery of Galantamine for Alzheimer's Disease Therapy | HTML
![Galantamine in the Treatment of Cognitive Decline in Patients with Vascular Dementia or Alzheimer's Disease with Cerebrovascular Disease | SpringerLink Galantamine in the Treatment of Cognitive Decline in Patients with Vascular Dementia or Alzheimer's Disease with Cerebrovascular Disease | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.2165%2F00023210-200317120-00004/MediaObjects/40263_2012_17120905_Fig3.jpg)
Galantamine in the Treatment of Cognitive Decline in Patients with Vascular Dementia or Alzheimer's Disease with Cerebrovascular Disease | SpringerLink
![Medica RCP |Reminyl LP 16mg | Indications | Effets indésirables | Composition | Route | all.price | Produits Alternatifs Medica RCP |Reminyl LP 16mg | Indications | Effets indésirables | Composition | Route | all.price | Produits Alternatifs](https://medicarcp.com/website/images/Products_flat/5803%20-%202.jpg)
Medica RCP |Reminyl LP 16mg | Indications | Effets indésirables | Composition | Route | all.price | Produits Alternatifs
![PDF) Antidementia drug treatment in dementia networks in Germany: Use rates and factors associated with treatment use PDF) Antidementia drug treatment in dementia networks in Germany: Use rates and factors associated with treatment use](https://www.researchgate.net/profile/Jochen-Rene-Thyrian/publication/277080912/figure/tbl3/AS:601619267850267@1520448619271/Logistic-regression-models-for-prediction-antidementia-treatment_Q320.jpg)
PDF) Antidementia drug treatment in dementia networks in Germany: Use rates and factors associated with treatment use
Steady-state pharmacokinetics of galantamine are not affected by addition of memantine in healthy subjects - Document - Gale OneFile: Health and Medicine
![A Long-Term Comparison of Galantamine and Donepezil in the Treatment of Alzheimer's Disease | SpringerLink A Long-Term Comparison of Galantamine and Donepezil in the Treatment of Alzheimer's Disease | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.2165%2F00002512-200320100-00006/MediaObjects/40266_2012_20100777_Fig5.jpg)
A Long-Term Comparison of Galantamine and Donepezil in the Treatment of Alzheimer's Disease | SpringerLink
![Galantamine in the Treatment of Cognitive Decline in Patients with Vascular Dementia or Alzheimer's Disease with Cerebrovascular Disease | SpringerLink Galantamine in the Treatment of Cognitive Decline in Patients with Vascular Dementia or Alzheimer's Disease with Cerebrovascular Disease | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.2165%2F00023210-200317120-00004/MediaObjects/40263_2012_17120905_Tab2.jpg)